title: Cyclic combination chemotherapy for metastatic breast cancer: comparison of two CMF schedules.
abstract: 104 nonrandomized patients suffering from metastatic breast cancer were treated with monthly cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). One group (group A, 44 patients) received low-dose CMF and another one (group B, 60 patients) received standard doses. In both cases, therapy was cycled every 29 days. Group A patients had a response rate of 50.7%, including 5 complete remissions. The median duration of response was 8.2 months. For group B patients, the response rate was of 68.1%, including 10 complete remissions. The median duration of response was 10.6 months. Toxicity was greater in group B patients, the main side effects being nausea, vomiting, leukopenia, thrombocytopenia, alopecia and stomatitis.
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D009362:Neoplasm Metastasis
chemical_list: D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate